Prusent 2mg (Prucalopride) 2mg

Prucalopride is a prokinetic agent that acts on the gastrointestinal motility pathway to relieve chronic constipation.

• Chronic idiopathic constipation: increases bowel movement frequency and improves stool consistency.

• Prucalopride selectively binds to 5‑HT4 receptors on the smooth muscle of the gastrointestinal tract, stimulating peristaltic activity and accelerating colonic transit without significant interaction with other serotonin receptor subtypes, thereby enhancing bowel motility in patients with constipation.

Prucalopride may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Headache: mild to moderate intensity.
• Nausea: occasional, often resolves with continued therapy.
• Abdominal pain: cramping discomfort in the lower abdomen.
• Diarrhea: loose stools, usually self‑limiting.
• Flatulence: increased intestinal gas.
• Dizziness: transient light‑headedness.

Serious or Rare Side Effects

• Severe abdominal pain: persistent or worsening pain requiring medical evaluation.
• Allergic reactions: rash, pruritus, or angioedema.
• Cardiac arrhythmia: rare reports of palpitations or irregular heartbeat.
• Intestinal obstruction: signs of blockage such as vomiting or inability to pass gas.
• Severe hypersensitivity: anaphylactic symptoms requiring emergency care.

Before initiating therapy, consider the following safety measures.

• Assess renal function: adjust use in patients with severe renal impairment.
• Evaluate cardiovascular status: avoid in uncontrolled arrhythmias or recent myocardial infarction.
• Check for hypersensitivity: discontinue if allergic reaction occurs.
• Use cautiously in inflammatory bowel disease: monitor for exacerbation of symptoms.
• Pregnancy and breastfeeding: safety not established; weigh benefits against potential risks.
• Store at ambient temperature: keep below 25 °C, protect from moisture and light.

Prucalopride may interact with other medicines; awareness of potential interactions helps maintain safety.

Major Interactions (Avoid)

• Concomitant use with other prokinetic agents: may increase risk of gastrointestinal adverse events.
• Strong CYP3A4 inhibitors: although prucalopride is minimally metabolized, co‑administration could raise plasma levels.

Moderate Interactions (Monitor Closely)

• Anticholinergic drugs: may diminish prokinetic efficacy.
• Opioid analgesics: can counteract the laxative effect of prucalopride.
• Diuretics: monitor for dehydration if diarrhea occurs.